A deficiency in a-galactosidase A (a-gal A) activity causes Fabry disease. Virus-based delivery of genes can correct cells and establish a sustained supply of therapeutic proteins. Recombinant lentiviral vectors (LVs) show promise in this context. We first demonstrate LV-mediated marking of peripheral blood (PB) cells by transduction/transplantation of hematopoietic stem/progenitor cells. Stable enGFP expression was observed in PB for 37 weeks. Next, we transplanted Fabry mice with bone marrow mononuclear cells (BMMNCs) transduced a single time with a LV encoding the human a-gal A cDNA. Sustained expression of functional a-gal A in Fabry mice was observed over 24 weeks. Plasma a-gal A activity from treated Fabry mice was two-fold higher than wild-type controls. Increased a-gal A activity, often to supra-normal levels, and reduction of globotriaosylceramide, a glycolipid that accumulates in Fabry disease, was observed in all organs assessed. In secondary bone marrow transplantations, Fabry mice showed multilineage marking of PB, splenocytes and BMMNCs, along with therapeutic levels of agal A activity in plasma and organs over 20 weeks. Lastly, we transduced mobilized PB CD34 + cells from a Fabry patient and observed corresponding enzymatic increases. Thus a single LV-mediated transduction of primitive hematopoietic cells can result in sustained correction for Fabry disease.
Introduction
Fabry disease is a lysosomal storage disorder (LSD) that is due to an inherited deficiency of the lysosomal enzyme a-galactosidase A (a-gal A; EC 3.2.1.22). 1 The disease is characterized by the systemic accumulation of galactosylsphingolipids, mainly globotriaosylceramide (Gb3). 2 Fabry disease has a prevalence of B1/40 000 males and is very heterogenous at the molecular level, with more than 245 mutations reported. 3 It also shows variability at the clinical level, with some patients having a variant or attenuated form of the disease. 4 Although enzyme replacement therapy (ERT) is currently available for Fabry disease with reports of improvement in some clinical and pathological manifestations, 5, 6 sustained and frequent administration of the factor is required.
Treatment of storage disorders using allogeneic stem cell transplantation (SCT) has been reported. 7, 8 In general, outcomes have been long-term but only partly effective. There are two major reasons limiting the clinical application of allogeneic SCT. First, there is a limited availability of human lymphocyte antigenmatched donors and a significant risk of treatmentrelated morbidity or mortality owing to severe graftversus-host disease (GvHD). 9 Secondly, non-modified hematopoietic stem/progenitor cells (HSPCs) and their progeny do not secrete therapeutic levels of target enzyme, which can be taken up at a distance by affected organs in a process termed 'metabolic cooperativity' or 'cross-correction'. 10, 11 Autologous SCT alleviates risks involved with GvHD and will likely be even more effective at systemic correction of LSDs and other disorders if the target cells have been genetically modified to over-produce and secrete the therapeutic enzyme before transplantation.
We have previously shown enhanced therapeutic intervention in Fabry mice by transplantation of syngeneic bone marrow (BM) transduced with oncoretroviral vectors (RVs) carrying the human a-gal A cDNA. [11] [12] [13] [14] A major hurdle to application of this approach in clinical studies for Fabry disease and other LSDs, however, is to accomplish efficient gene transfer into true HSPCs, which can then be transplanted to achieve stable, robust and long-term expression of corrective genes in progeny cells. This is a challenging task for the RVs currently in clinical trials. This is primarily due to modest gene transfer efficiencies because the virus is often of low titer; also, there are negative effects on the graft itself owing to extended ex vivo cultures of the target HSPCs in less than optimal cytokine cocktails. Indeed, this scenario was likely borne out in a clinical gene therapy trial for Gaucher's disease, another LSD. 15 Lentiviral vectors (LVs) can obviate some of these issues. They can transduce not only dividing cells but also less actively dividing cells like HSPCs. 16 A single infection course can also give higher gene transfer efficiencies, as appropriately pseudotyped virions can be concentrated by ultracentrifugation to high titers and components of this complex viral vector actually aid in integration. Furthermore, it has been well documented that LV-infected human HSPCs can maintain their engraftment and differentiation ability in vivo (non-obese diabetic (NOD)/severe combined-immunodeficient (SCID) mouse xenotransplantation model). 17 Large animal models also demonstrate higher and better sustained transgene expression with LVs 18 (R Donahue, NIH, personal communication). In addition, shorter ex vivo cell manipulations can maintain more HSPCs; this may allow a shorter duration of white blood cell (WBC) engraftment. This is especially important in clinical settings, as severe infection owing to sustained neutropenia is one of the most critical complications in autologous SCT.
Here we set out to examine the use of LVs in the context of Fabry disease to accomplish efficient transduction of HSPCs under conditions that allow maintenance of hematopoietic stem cell properties. We first transduced and transplanted enriched murine HSPCs with a marking vector and monitored high levels of enGFP expression in a prominent percentage of PB cells over 37 weeks. Following this success, we engineered a therapeutic recombinant LV for correction of Fabry disease. We monitored functional enzyme activity and the potential to correct disease as assessed by reduction of Gb3 in Fabry mice transplanted with transduced primitive cells. We observed substantial expression of human a-gal A over 24 weeks in many organs relevant to the disorder. Next, we demonstrated that such expression successfully corrected the accumulation of Gb3 at 24 weeks in all organs analyzed. In addition, BM from primary corrected mice was utilized in secondary bone marrow transplantations. Functional multi-lineage gene marking was observed as was an increase in a-gal A activity and a reduction in Gb3 levels, demonstrating successful gene transfer into re-populating HSPCs and sustained secretion of the corrective factor from transduced cells. These results indicate that transplantation of single-time LV-transduced autologous HSPCs may represent a long-sought therapeutic option for Fabry disease patients and possibly for other LSDs.
Results
Long-term and stable functional expression of enGFP in PB cells of Fabry mice transplanted with HSPCs transduced with a marking LV We first infected primitive BMMNCs collected from 5-fluorouracil (5-FU)-treated donor Fabry mice with LV/enGFP 19 (SIN; EF-1a promoter) at an estimated multiplicity of infection (MOI) of 20 and co-stained transduced cells for cell surface markers after 2 days of culture in enriched media. Total infected cells were found by flow cytometry analyses to be B37% positive for enGFP expression (data not shown). We found 2.7% of total infected cells singly positive for c-kit expression, and 1.2% of total cells were doubly positive for c-kit and enGFP expression (data not shown). For Sca-1, 23.0% of total infected cells were positive for expression and 9.7% of total infected cells were doubly positive for Sca-1 and enGFP expression (data not shown). Likewise for CD4 and CD8 expression, 8.6 and 4.2% of total infected cells were positive for these antigens; 3.7 and 1.3% of total infected cells were doubly positive for CD4 or CD8 and enGFP expression, respectively (data not shown). Lastly, 2.1% of total infected cells were positive for CD19 expression with 0.9% of total infected cells doubly positive for CD19 and enGFP expression (data not shown).
We next examined the capacity for long-term functional expression mediated by LV transfer of a marking gene into HSPCs from Fabry mice. BMMNCs from Fabry mice were transduced with LV/enGFP at an estimated MOI of 30 and transplanted into lethally irradiated Fabry mice. PB samples were collected from individual mice at various days after transplantation and analyzed. We next generated a recombinant LV that engineered expression of a-gal A (LV/a-gal A). 19 Owing to the high gene transfer levels we have observed using LVs 19 (data not shown), we constructed this vector in a monocistronic form without a cell surface marker that could be used for functional enrichment of transduced cells.
14 This LV was pseudotyped with VSV-g as we have carried out before. 20 We assessed the efficacy of our marking and therapeutic LVs in immortalized, patient-derived B cells.
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For these experiments, 0.2 Â 10 6 cells were infected a single time at various estimated MOIs using LV/enGFP and LV/a-gal A. MOIs for the LV/a-gal A construct were estimated by comparing p24 levels with those functional titer outcomes obtained on infected test cells with similar p24 values from the LV/enGFP construct (data not shown).
As shown in Figure 2a , 3 weeks after infection varying functional transduction rates were observed in the LV/ enGFP-infected Fabry patient B cells depending on the starting MOI used. Figure 2b shows that some MOIs generated supranormal levels of intracellular a-gal A activity in Fabry patient B cells infected with LV/a-gal A. Indeed, at an estimated MOI of 20, levels were 44-fold higher than normal B-cell a-gal A activity (Figure 2b ). Supranormal levels of intracellular a-gal A activity were also observed with an estimated MOI of 10. Note that these therapeutic transgene expression levels are substantially higher with a single recombinant LV infection than we observed previously with four oncoretroviral infections. 11 With lower MOIs, lysate a-gal A activity was lower than normal B cell levels but still above background Fabry patient B cell a-gal A activity even at an estimated MOI of 0.1.
Secreted a-gal A activity correlated with intracellular a-gal A activity. Fabry patient B cells infected with the LV/a-gal A construct at an estimated MOI of 20 secreted two-fold more a-gal A activity than normal cells ( Figure  2c ). Importantly, in this assay, detectable levels of secreted a-gal A activity above background were even observed from cells infected at an estimated MOI of 1 ( Figure 2c) .
Lastly, to better correlate a-gal A activity with integrated vector copy number for infected Fabry patient B cells, we performed Southern blot analyses on genomic DNA to gauge the number of proviral integrants relative to the estimated starting MOI. These results are shown in Figure 2d . At an estimated MOI of 20, the LV/enGFP construct yields an average of 3 stable integrants/cell. As expected, this result decreased proportionally as lower estimated MOIs were employed. Importantly, this detailed analysis demonstrated that our effective MOI using the therapeutic LV/a-gal A construct was actually about three-fold lower than that seen with the LV/enGFP vector ( Figure 2d ).
Taken together, these data demonstrate encouragingly that intracellular a-gal A correction can be observed at lower MOIs such as 1 and that this can effectively lead to appreciable a-gal A secretion even when the proviral Increased a-gal A activity in the plasma of Fabry mice transplanted with LV/a-gal A-transduced cells
To assess the potential of therapeutic LV-corrected hematopoietic cell transplantation in this LSD, we transduced HSPCs from a-gal A-deficient Fabry mice with the LV/a-gal A or the control LV/enGFP and transplanted them into Fabry mice. Cells were transduced a single time in an overnight procedure (total viral contact time: 12 h) at an estimated functional MOI of 10 and 2.4 mg p24/1 Â 10 6 cells for the LV/enGFP and the LV/a-gal A, respectively. In the primary bone marrow transplantation (BMT) experiment, LV/a-gal A-treated Fabry mice (n ¼ 9), LV/enGFP-marked Fabry mice (n ¼ 8), untouched Fabry mice (n ¼ 8) and wild-type (WT) C57Bl/6 mice (n ¼ 8) as a strain control were assessed. Whole blood was collected from all animals in each group at various time points. Complete blood counts were performed at the same time. No leukocytosis was observed throughout this experiment. WBC counts recovered beyond 1500 cells/ml 2 weeks after BMT without any life-threatening infection. Plasma was isolated and a-gal A activity was measured. Cumulative results over 24 weeks are shown in Figure 3 . a-Gal A activities increased significantly (Po0.001) in the therapeutically treated group compared to the untouched group, the LV/enGFP-marked group or the WT group. This increase peaked at 2 weeks and then was stable and consistent until termination of the experiment (24 weeks). Indeed, plasma a-gal A activity levels were above normal values throughout the experiment. These levels were higher and more stable than those we previously observed using a therapeutic recombinant oncoretrovirus 13 even with pre-selection of functionally transduced cells before transplantation. 14 Increased a-gal A activity and reduced Gb3 levels in the organs of treated Fabry mice Twenty-four weeks after the primary BMT, we killed the animals. We determined a-gal A activity in extracts of various organs from each of the treated and control mice. We also analyzed the Gb3 levels in those organs by HPLC. 21 In the LV/a-gal A-treated group, a-gal A activity in all the organs assessed increased significantly (Table 1 ). In the LV/a-gal A-treated group, a-gal A activity in the liver and spleen increased significantly to 132 and 251% of normal, respectively. With these levels of enzyme activity, Gb3 levels decreased to nearly normal levels (Tables 1 and 2 ). In the heart, one of the most critically affected organs in Fabry patients, a-gal A activities increased up to 124% of normal levels, and Gb3 levels also decreased to the normal range in the therapeutically treated group. Notably, in the kidney, which has been one of the most affected and challenging organs to correct for Fabry disease using ERT and gene therapy approaches, 13, 14, 22, 23 a-gal A activities increased to B25% of normal levels, which is likely to be therapeutically relevant (Table 1) . Even though Gb3 levels in kidneys of these treated animals did not fully reduce to the normal range, substantial and significant decreases of Gb3 levels were observed ( Table 2) . We also observed a significant increase in a-gal A activity in the brain (Po0.01). This potentially therapeutic outcome is especially important if we wish to apply this treatment schema to other LSDs that have extensive central nervous system (CNS) involvement such as Farber disease. 24, 25 Another important finding from this study was that the variability of the levels of disease correction between each animal was very small; we previously saw relatively large variations between organ and Gb3 levels in oncoretrovirally treated Fabry mice. 13, 14 At the point of killing, we collected BMMNCs from the primary transplanted Fabry mice. A portion of these cells were seeded into Methocult for short-term colony assays. Granulocyte and granulocyte-macrophage colonies were collected from separate plates of cells derived from Fabry mice receiving LV/a-gal A therapeutically transduced cells and LV/enGFP-transduced controls. Colonies were subjected to PCR analyses for the presence of the integrated provirus. From the mice receiving the LV/ enGFP-transduced cells, we observed collectively 36/ 51 ¼ 71% colonies positive for the integrated provirus (data not shown). Similar results (53/82 ¼ 65%) were obtained for the colonies from the LV/a-gal A-infected group (data not shown). These data are consistent with the results obtained in our extended LV/enGFP study ( Figure 1) . They indicate stable gene transfer and that metabolic cooperativity originating from this transduced cell population can yield positive systemic results that persist over time.
Secondary BMT
Sustained a-gal A expression in plasma and all organs analyzed was observed for 24 weeks in LV/a-gal A-transduced BM recipients. This strongly suggests that the enzymatic rescue resulted from the transduction of early hematopoietic stem cells capable of self-renewal. To directly evaluate this hypothesis, a second set of naïve Fabry mice were transplanted after lethal irradiation with BM cells collected at 24 weeks from the primary BMT recipient animals (as above). Measurements of plasma a-gal A activity at 8, 16 and 20 weeks after secondary transplantation revealed sustained and therapeutically relevant levels of a-gal A activity that reached B46% of normal levels ( Figure 4) . In contrast, a-gal A activity was absent in secondary recipients of LV/ enGFP-transduced and transplanted BM, as expected. Next, a-gal A activity in organs was measured in the secondary recipients upon killing at 20 weeks. a-Gal A activity in all organs measured except kidney was significantly higher in the LV/a-gal A-recipient Fabry mice than in the LV/enGFP recipients (Po0.01) ( Table 3) . To postulate whether this was owing to multilineage differentiation of transduced HSPCs, enGFP expression on PB, splenocytes and BMMNCs was analyzed from the control group of LV/enGFP transplanted Fabry mice. EnGFP expression was observed on CD4 + , CD8 + and CD19 + splenocytes and Gr-1 + and Mac-1 + BMMNCs ( Figure 5) . The relatively lower a-gal A activities observed in LV/a-gal A-treated secondary recipient Fabry mice compared to the primary animals are consistent with previous studies that report diminished reconstitution capacity with serial transplantation. 26 Together, these observations demonstrate that efficient transduction of HSPCs leads to sustained and systemic correction of the a-gal A deficiency.
Efficient and functional LV-mediated marking and therapeutic transgene expression in Fabry patient G-CSF-mobilized, CD34
+ PB cells
To determine the amenability of this vector system towards clinical application, we assessed the efficiency of our marking and therapeutic LV transduction protocol into Fabry patient-derived, G-CSF-mobilized PB CD34 + cells. 27 Collection of these cells from severely affected 
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patients is less invasive compared to BM aspiration and may be more practical in the clinical setting. Cells were maintained in a cytokine cocktail conducive to maintenance of primitive HSC properties 28 and transduced 
Discussion
We have recently shown long-term and sustained enzymatic correction of Fabry mice for up to 28 weeks by direct intravenous injection of a therapeutic LV into neonatal recipient animals. 19 This delivery method does not require invasive pre-conditioning before gene delivery owing to the immature nature of the neonatal immune system. Vector integration was also aided by the fact that many tissues were undergoing rapid cell division. However, this approach is only clinically applicable when there has been an accurate prenatal diagnosis. Unlike other LSDs, Fabry disease has a slow progression -average age of onset is 10.1 years old and the average age of diagnosis is 21.9 years old. 29 In addition, whereas we did not observe any problems in that study and did not observe actual germline transmission of the LV, safety concerns for that delivery schema are more complicated than for ex vivo transductions followed by transplantations. Thus it is presently more clinically relevant to develop a single curative treatment option for those diagnosed beyond the neonatal period, especially for symptomatic adult patients.
In this work, we demonstrated efficient and long-term LV-mediated gene transfer into syngeneic HSPCs of Fabry mice with a single dose of concentrated viral supernatant. In contrast to our earlier RVs, 14 we employed a recombinant LV that engineered expression of a-gal A (LV/a-gal A) in a monocistronic format. As we had previously observed high gene transfer levels using this vector system, we did not use a cell surface marker that could be used for enrichment of transduced cells. 14 Our therapeutic levels of transgene expression in this present study using the monocistronic vector construct facilitates practical application of this approach in the Lentivirus-mediated correction of Fabry disease M Yoshimitsu et al clinic without possible confounding effects due to coexpression of a marking transgene. 30 A downside of this, however, is that accurate titering of functional vector stocks and long-term detection of vector in transplanted recipients is more complicated.
Here our in vitro and in vivo studies showed that transduced cells not only expressed the functional therapeutic transgene product intracellularly but also secreted the corrective factor at appreciable levels. LV/ a-gal A-treated mice showed supranormal a-gal A activity in plasma over 24 weeks post BMT (Figure 3) . This is one of the most important advantages of gene therapy over allo-BMT alone in some inherited disorders -unmodified allogeneic HSPCs secrete less enzyme and lead to insufficient correction of disease. 10 In addition, as expected, a-gal A activity in the therapeutically transduced recipients was significantly higher in all organs assessed. It is noteworthy that this level of organ a-gal A activity was higher (to our knowledge) than that of any other Fabry disease gene therapy experiments to date in all organs. 13, 14, 19, 23, [31] [32] [33] This finding indicated efficient in vivo metabolic cooperativity of enzyme-deficient, affected cells from transduced and enzyme-overproducing cells (Table 1) . These data also suggest that correction of only relatively a small number of key cells, such as repopulating HSPCs, may be sufficient to cure Fabry disease. Importantly, Fabry disease is also an appropriate gene therapy target in this regard, as overexpression of a-gal A to high levels in various organs (up to 11 000-fold over background) in transgenic mice is well tolerated. 34 Notably, in this study, we also found a significant increase of a-gal A activity in the brain of treated mice. We have observed this effect before 13 but not to the present higher level. Whereas we did not identify the enzyme source in the CNS, Biffi et al. 10 have recently shown similar CNS correction in another LSD mouse model and identified gene-modified BMMNC-derived microglial cells as the possible enzyme source. This finding is of importance if we apply this therapeutic system to other LSDs that have severe CNS involvement such as Farber disease. 24, 25 Furthermore, the reduction of Gb3 in many clinically relevant organs proved that the secreted form of a-gal A derived from LV-transduced HSPCs was fully functional in vivo (Table 2) .
We performed colony PCR assays and then a secondary BMT to confirm LV-mediated transduction of more primitive hematopoietic cells and also looked for an extended corrective effect. Twenty weeks after the secondary transplantation, we found sustained and clinically relevant levels of a-gal A activity in plasma and in multiple organs (Table 3 and Figure 4 ). These results indicated that HSPCs were able to maintain their self-renewing capacity even after ex-vivo LV-mediated gene modification. Moreover, enGFP expression in PB mononuclear cells (MNCs), splenocytes and BMMNCs from LV/enGFP-transduced primary and secondary transplanted mice directly proved the capability of multi-lineage differentiation of LV-manipulated HSPCs ( Figure 5 ). This is in accordance with previous observations. 17 In addition, in this study, we were able to efficiently transduce Fabry patient-derived CD34 + hematopoietic cells with both the therapeutic and control gene-marking LVs. This is an important finding in order to appropriately gauge the effectiveness of this viral construct in transducing these primitive repopulating target cells as preclinical assessment for this vector system. In the future, we will further examine in vivo differentiation and proliferation of therapeutically LVtransduced HSPCs using a NOD/SCID mouse xenotransplantation model and a non-human primate model. Both of these studies are currently underway in our laboratory.
Successful somatic gene therapy trials have been reported with oncoretroviruses. [35] [36] [37] Unfortunately, recent outcomes from a gene therapy clinical trial showed that some patients developed leukemias after oncoretrovirus-mediated ex vivo gene transfer into HSPCs. 38 A follow-up study from the same group has revealed that LMO2 oncogene activation due to oncoretroviral integration may be the possible cause of two of the leukemias. 39 Recently, extensive studies showed the difference in the nature of integration sites between oncoretroviruses and LVs. 40, 41 Oncoretroviruses favor transcriptional start sites and LVs have a tendency to integrate throughout regions rich in expressed genes. This differential feature of LV integration might reduce the possibility of oncogene activation or tumor suppressor gene inactivation. Nonetheless, more studies need to be performed in this area.
A number of HSPC-targeted studies using LVs have been performed in other LSDs and have shown promising results owing to robust transgene expression as we also observed in this study. 10, 42, 43 In conclusion, we demonstrated here the potential of LVmodified HSPCs transduced with a single vector application to correct Fabry disease in the mouse model of the disorder. We also demonstrated effective gene transfer into primitive human hematopoietic cells from a Fabry patient. These results are a critical step forward for prospective clinical application. Further studies will address the safety of LV-mediated HSPCs gene therapy, and its possible application to other LSDs as well. Our present results obtained with the mouse model of Fabry disease demonstrate that the procedure can restore enzyme activity and reduce Gb3 in damaged organs and may possibly provide lifelong curative treatment with a single intervention.
Materials and methods

Lentiviral vector production
A monocistronic therapeutic HIV-1-based recombinant LV for the correction of Fabry disease was constructed by removing the IRES/human CD25 element from pHR'cPPT-EF1a-(human)a-gal A-IRES-huCD25-WPRE-SIN 19 to yield the plasmid pHR'-EF1a-a-gal A-WPRE-SIN (LV/a-gal A). VSV-g-pseudotyped LVs, including an enGFP marking vector (LV/enGFP), 19 were generated by transient transfections of 293T cells (ATCC) using the three-plasmid system (LV plasmid construct, packaging plasmid pCMVDR8.91 and the VSV-g envelope-coding plasmid pMD.G) as described previously. 19 Vector supernatants were collected 72 h after transfection and concentrated by ultracentrifugation at 50 000 g for 2 h. The concentrated LV/enGFP supernatants were serially diluted and titered on HeLa cells (ATCC). Flow cytometric analyses for enGFP expression were performed 72 h after infection using FACSCalibur (BD cells were infected a single time with LV/enGFP and LV/a-gal A LV in various doses in the presence of 8 mg/ ml of protamine sulfate. Secreted a-gal A activity from transduced cells was measured from 2.5 Â 10 6 cells seeded in 5 ml RPMI medium (Sigma, Oakville, ON, Canada) after 4 days of culture. A Southern blot was performed to determine gene copy number. Genomic DNA was extracted as described 44 from transduced and control Fabry B cells. A 5 mg portion of genomic DNA was digested with both EcoRI and HindIII (New England Biolabs, Ipswich, MA, USA) and separated by 0.8% agarose gel electrophoresis. Separated DNA fragments were washed in alkaline buffer and transferred onto a positive charged nylon membrane (Bio-Rad, Hercules, CA, USA) following standard alkaline transfer. 44 A 746 bp fragment containing the WPRE sequence was amplified by PCR (forward primer: 5 0 -TGC TCC TTT TAC GCT ATG TGG-3 0 ; reverse primer: 5 0 -TCG TTG GGA GTG AAT TAG CC-3 0 ) by using the PCR DIG Probe Synthesis kit (Roche) according to the manufacturer's instructions and used as a probe for Southern hybridization. Southern hybridization was carried out using a DIG Luminescent Detection kit (Roche) according to the manufacturer's instructions. CSPD (Roche) was used a substrate for alkaline phosphatase. WPRE sequence standards were serial dilutions of the LV/a-gal A plasmid DNA in human genomic DNA. The results were analyzed using NIH Image software and presented as copies/genome.
Mobilized peripheral blood (mPB) CD34 + cells were obtained from a Fabry patient using protocols approved by the NIH after obtaining informed consent.
27 CD34 + cells were isolated from mononuclear cells using Midi-MACS columns (Miltenyi Biotech, Auburn, CA, USA). Purity of enriched cells was more than 99% for CD34 expression as determined by flow cytometric analyses (data not shown). CD34 + cells were cultured in Stem Span SFEM expansion medium (Stem Cell Technologies, Vancouver, BC, Canada) for 20 h in the presence of 10 ng/ml human interleukin-6 (IL-6), 100 ng/ml human Flt3 Ligand (Flt3-L), 100 ng/ml human thrombopoietin (TPO) and 100 ng/ml human stem cell factor (SCF) (all growth factors were purchased from R&D Systems, Minneapolis, MN). The following day, cells were resuspended in concentrated LV supernatants (3 mg/p24 antigen for LV/enGFP and LV/a-gal A) at a concentration of 2 Â 10 6 cells/ml and cultured on Retronectincoated (5 mg/cm 2 ) plates (Takara Mirus Bio, Shiga, Japan). The supernatant was supplemented with the same cytokine cocktail used above along with 8 mg/ml protamine sulfate (Sigma). Flow cytometric analyses were performed 72 h later using FACSCalibur to examine enGFP expression on Fabry mPB CD34 + cells. a-Gal A and glucocerebrosidase (GC, another lysosomal enzyme) activity in cell lysates was measured as before.
14 Transduction of murine HSPCs: primary and secondary BMT a-Gal A-deficient Fabry mice 21 were bred at the University Health Network (UHN). Animal experimentation followed protocols approved by the UHN Animal Care Committee. To enrich for primitive stem/progenitor cells, 6-to 10-week-old male Fabry mice were injected intraperitoneally with 5-FU (150 mg/kg) (Sigma). Four days later, Fabry mice were killed and the BM was harvested by flushing the femurs and the tibias. BMMNCs were isolated over a Nycoprep (AXIS-SHIELD, Oslo, Norway) density gradient. For transductions, 1 Â 10 6 cells/ml were exposed to LV/enGFP (1 Â 10 7 infectious particles/ml) or LV/a-gal A (2 mg viral p24/ml) in Stem Span SFEM medium (Stem Cell Technologies) for 20 h in the presence of 8 mg/ml protamine sulfate (Sigma), 10 ng/ml murine IL-6, 100 ng/ml murine Flt3-L, 100 ng/ml murine TPO, and 100 ng/ml SCF (all from R&D Systems). Infections were performed on fibronectin-coated (5 mg/cm 2 ), non-tissue culture-treated, plates. Vector-transduced cells (approximately 5 Â 10 5 /mouse) were injected via the tail vein into 8-week-old lethally irradiated (11 Gy) recipient male Fabry mice. Age-matched Fabry mice were used as untouched controls. Age-and strain-matched C57BL/6 mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and used as wild-type controls. For the secondary BMT experiment, BMMNCs from primary BMT mice were collected at organ harvest as described above. For these experiments, 2 Â 10 6 BMMNCs from LV/a-gal-A or LV/enGFP-transduced and transplanted mice were injected via the tail vein into secondary 8-week-old lethally irradiated (11 Gy) naïve Fabry mice.
For colony PCRs to detect the frequency of proviral integrants, bone marrow was flushed from the femurs and tibias of primary recipient Fabry mice. Mononuclear cells were isolated by Ficoll (GE Healthcare, Piscataway, NJ, USA) gradient purification and then used for secondary transplant (above) or plated into Methocult media M3434 (Stem Cell Technologies) at a density of 3 Â 10 5 cells/35-mm dish. Cultures were grown for 14 days after which granulocyte and granulocyte-macrophage colonies were collected. DNA from each colony was isolated using the Puregene DNA Isolation Kit (Gentra Systems, Minneapolis, MN, USA). PCR was then performed to detect a 123 bp fragment of the WPRE element found in the lentiviral backbone (primers 5 0 -CTT CCC GTA TGG CTT TCA TT-3 0 and 5 0 -GTT GCG TCA GCA AAC ACA GT-3 0 ) using the following conditions: 30 cycles of 941C for 45 s, 601C for 30 s and 721C for 15 s. As a control for DNA integrity, a 226 bp fragment of mouse genomic b-actin was amplified as described. 45 PCR products were analyzed by electrophoresis on 2% agarose gels and scored as either positive or negative for the provirus product. supplemented with cytokines as above. Cells were stained using the following antibodies conjugated to either phycoerythrin (PE) or allophycocyanin (APC): a-CD4-PE, a-CD8-APC, a-CD19-PE, a-c-kit-APC, or aSca-1-PE. BMMNCs isolated from the secondary Fabry mouse recipients were stained using a-CD4-PE, a-CD8-APC, a-CD19-PE, a-Gr-1-PE, or a-Mac-1-APC. All antibodies were obtained from BD Biosciences Canada (Mississauga, ON, Canada). Cells were then analyzed by flow cytometry using a FACSCalibur (BD) and data were analyzed using CellQuest software (BD).
a-Gal A specific activity assay and HPLC quantitation of Gb3 levels a-Gal A activity was measured by a microtiter-platebased fluorometric assay as before.
14 Briefly, samples were added to a microtiter-plate reader (Dynex, Chantilly, VA, USA) and the 4-methylumbelliferone product was determined quantitatively by comparison to known standards (Sigma). As a control, GC activity was measured in parallel.
14 Frozen mouse tissue samples were homogenized with a tissue homogenizer for 10 s twice in the assay buffer (28 mM citric acid/44 mM disodium phosphate, pH 4.4) with 5 mg/ml sodium taurocholate before sonication. HPLC analyses of Gb3 levels in mouse organ extracts were performed as described. 17 The protein concentration of assay samples was determined by the BCA Protein Assay Kit (Pierce, Rockford, IL, USA). a-Gal A activity and Gb3 levels in each sample were measured in triplicate.
Statistics
Data are presented as results7standard error of the mean (S.E.M.). Statistical comparisons were obtained by analysis of variance with the Bonferroni multiple comparison test using InStat (GraphPad Soft Ware, San Diego, CA, USA). P-values less than 0.05 were considered statistically significant.
